OTR3 has a strong pipeline that
relies on the considerable potential 
of the RGTA® technology

Pipeline
Pipeline

01

Our Pipeline

01

Our Pipeline

Pipeline
Pipeline
Pipeline

OTR3 focuses on high potential programs
including some award winning key projects.

02

Our R&D
Projects

02

Our R&D
Projects

OTR3 focuses on key development projects with high potential, with the aim of exploiting the versatility of the RGTA® technology to provide to patients new healthcare products that really matter.

The following development programs, relying on the regenerating potential of RGTA® molecules,  are just only a fraction of the technology’s potential, and are to date the closer to market.

The excellence and potential of OTR3’s Pipeline has been confirmed by awards and grants (H2020 SME Instrument, Medicen Label, ANR grant)

Ischemic stroke

RGTA® treatment aims at improving functional recovery by neuronal protection

Alzheimer Disease

Helping patients by blocking Tau protein propagation and protecting neuronal environment

Oral Mucositis

RGTA® should represent a new solution for patient to heal ulcerations and reduce pain

Tendonitis
(horse)

Clinical Trial (RCT) showed that RGTA® improves tendon healing and results in faster recovery

Tendonitis

RGTA® could bring to a potential treatment to allow better patient recovery by tendon regeneration

Epidermolysis bullosa

A new therapeutic solution for skin wound healing and associated pain reduction

Pipeline
Pipeline
Home
Home

© 2018 – OTR3 – All rights reserved
Design + Development by Popcorn 66

ADDRESS

4, rue Française
75001 Paris, France

© 2018 – OTR3 – All rights reserved
Design + Development by Popcorn 66